The overexpression of CCNF was an adverse prognostic factor in terms of OS in patients with KIRC, KIRP, LIHC, LUAD, pancreatic ductal adenocarcinoma (PDAC), Sarcoma (SARC), STAD, TGCT, THYM and UCEC (Figure 3A), and an adverse prognostic factor in terms of RFS in patients with bladder carcinoma (BC), HNSC, KIRC, KIRP, LIHC, LUAD, LUSC, PDAC, SARC, thyroid carcinoma (THCA) and UCEC (P<0.05) (Figure 3B). Here, CCNF is linked to breast cancer.